Javeria Hamraa

Dr. Javeria Hamraa

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2026 in Reviews in Medical Virology
Verified
Journal Article
Closed access
HCHuynh Tran Bao Chau
Huynh Tran Bao Chau
BMBui Cong Minh
Bui Cong Minh
Jeza Muhamad Abdul AzizJeza Muhamad Abdul Aziz
Jeza Muhamad Abdul Aziz
HVHoang Bao Tran Van
Hoang Bao Tran Van
BTBui Nguyen Ha Tien
Bui Nguyen Ha Tien
Nguyen Tien HuyNguyen Tien Huy
Nguyen Tien Huy

6 August 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
NNNathalie Nasser
Nathalie Nasser
Hassan AliHassan Ali
Hassan Ali
JHJaveria Hamraa
Javeria Hamraa
MAMuhammad Asad Ali
Muhammad Asad Ali
HBHajira Bibi
Hajira Bibi
LYLaiba Yasin
Laiba Yasin
The interplay between the human gut microbiota and the peripheral immune system significantly affects the efficacy of immune checkpoint inhibitors (ICIs) in cancer therapy. Despite this profound connection, the practical implications of microbiota dysbiosis in cancer immunotherapy ICIs & and CAR-T remain intricate and poorly understood in practical terms. This paper offers a comprehensive review of current literature on the role of gut microbiota dysbiosis in tumor development, and emerging microbiota modulation interventions, with a focus on fecal microbiota transplantation (FMT). FMT is a cost-effective therapeutic avenue, particularly in addressing diseases rooted in antibiotic-resistant bacteria, such as Clostridium difficile. Here we provided insights into the applications of FMT and other gut microbiota therapies in the landscape of cancer treatment, emphasizing their influence on the tumor microenvironment and the efficacy of ICIs with suggestions for future research directions and their implications for clinical practice.

3 September 2024 in Qeios Preprints
Verified
Preprint
Open access
PDF file
JHJaveria Hamraa
Javeria Hamraa
FKFeriha Fatima Khidri
Feriha Fatima Khidri
SSSania Saeed
Sania Saeed
OOOluwabusola Elizabeth Oni
Oluwabusola Elizabeth Oni
SASundus Anbreen
Sundus Anbreen
SSSumbal Shaukat
Sumbal Shaukat
The SARS-CoV-2 virus, responsible for the COVID-19 pandemic, has continuously evolved since its emergence. Among its variants, the Omicron lineage has become globally dominant, displaying a diverse range of sublineages. Two significant sublineages within Omicron are EG.5 and BA.2.8, which have gained attention due to their unique characteristics and potential implications. EG.5 is characterized by a constellation of mutations, including N501Y, L452R, and D614G. Similarly, BA.2.8 carries the L452Q and P681R mutations, which enhance its ability to evade antibodies elicited by prior infection or vaccination. Similar to those in EG.5, the clinical severity and impact of BA.2.8 on public health measures are still being assessed. These sublineages, with their unique genetic profiles and transmissibility characteristics, pose challenges to virulence response efforts. Continued surveillance, genomic sequencing, and research are essential to understand their behavior, assess their impact, and inform public health strategies accordingly. By a comprehensive synthesis of the literature, genomic data, and epidemiological insights, this study provides an analysis of Omicron mutations’ transmission dynamics and clinical implications associated with these variants. The significance of variant surveillance in informing public health responses to the COVID-19 pandemic is underscored, highlighting the critical role of genomic sequencing in tracking viral evolution and guiding interventions. This manuscript aims to elucidate the mechanisms underlying variant emergence, assess vaccine effectiveness against emerging strains, and explore the broader implications for global public health. This study provides insights into vaccine-induced immunity and the potential impact of variants on vaccine efficacy. Overall, this communication aims to inform public health practitioners, policymakers, and researchers engaged in the battle against COVID-19, offering actionable insights to mitigate the spread of the virus and improve pandemic response strategies.